Two pivotal cell therapy programs are advancing, with LYL273 showing strong response rates and safety improvements in metastatic colorectal cancer and ronde-cel leading in large B-cell lymphoma. Key data updates and a BLA submission are expected within the next year, positioning both products for commercial launch.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.